New research in The FASEB Journal suggests that a chimera design of DNA and small DNA with a companion contrast agent to facilitate uptake allows antibodies to cross cell membranes
Scientists have identified a quantitative method to measure changes in biomarkers, which may reduce or eliminate the need for invasive biopsies. The method, described in the February 2016 issue of The FASEB Journal uses a novel chimera design of DNA and small DNA with a companion contrast agent to allow antibodies to cross cellular membranes. Once across these membranes, the tissues being evaluated can be imaged a much greater level of detail than what is possible now.
This could significantly impact the use of gene therapy and stem cell therapy, as well as lead to better diagnosis and treatment of cancer, Alzheimer’s disease, viral infections, HIV, herpes and prion diseases.
“Dr. McCoy does not have to perform a biopsy to know the disorder and cure patients without surgery in Star Trek,” said Philip K. Liu, Ph.D., a researcher involved in the work from the Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital in Charlestown, Massachusetts. “This finding avoids biopsy and it makes a ‘McCoy diagnosis’ one step closer to reality.”
To make this advance, Liu and colleagues used three groups of mice. This first group received a complete chimera (antibodies to rhodopsin linked to a reporter agent and small DNA), the second group received a chimera without DNA. A third group had damaged retinas and a less rhodopsin. The first group showed a presence of the chimera in the retina using MRI (in vivo) or TEM (ex vivo). Uptake and targeting of complete chimera were compared in the third group and the first group. Results showed that the third group had significantly less uptake of chimera.
“There will be a time when biopsies are considered primitive,” said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal, “and as developments in imaging technology and techniques improve our capabilities, the need for invasive, and sometimes painful, biopsies is greatly decreased.”
The Latest on: Invasive biopsies
via Google News
The Latest on: Invasive biopsies
- Breast Biopsy Industry Market Growth, Trends, Size, Share, Players, Product Scope, Regional Demand, COVID-19 Impacts and 2026 Forecaston July 10, 2020 at 12:42 am
According to the latest market research report “Breast Biopsy Industry Market Growth, Trends, Size, Share, Players, Product Scope, Regional Demand, COVID-19 Impacts and 2026 Forecast” released by ...
- Rising Cancer Cases is Pushing Demand for Liquid Biopsy in the Global Marketon July 9, 2020 at 3:40 pm
According to a new market research report launched by Inkwood Research, the Global Liquid Biopsy Marketis anticipated to propel at 20.50% of CAGR between 2020 and 2028. In terms o ...
- Study sheds light on how cancer spreads in bloodon July 9, 2020 at 9:26 am
A new study sheds light on proteins in particles called extracellular vesicles, which are released by tumor cells into the bloodstream and promote the spread of cancer. The findings suggest how a ...
- Technological Development is propelling the Global Liquid Biopsy Market Growthon July 9, 2020 at 5:03 am
According to a new market research report launched by Inkwood Research, the Global Liquid Biopsy Market is projected to generate $5.76 billion in terms of revenue by 2028, with a growth rate of 20.50% ...
- Liquid Biopsy Market Size to Touch USD 17,372.28 Million at 28.0% CAGR by 2022on July 9, 2020 at 2:05 am
Liquid Biopsy Market Analysis The global liquid biopsy market is likely to touch USD 17,372.28 million at a whopping 28.0% CAGR between 2014- 2022, ...
- Aspiration & Biopsy Needles Market Exploring Future Growth 2020-2030 and Key Players - CONMED, BD, Cardinal Healthon July 8, 2020 at 9:57 am
Market Industry Reports (MIR) has published a new report titled "Aspiration & Biopsy Needles Market- Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020–2030." According to the ...
- Study explores if insurance is keeping pace with trends in targeted cancer therapyon July 7, 2020 at 1:39 pm
New research from the University of California, San Francisco (USCF) and City of Hope in the July 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network examines coverage trends for ...
- Payer Coverage for Liquid Biopsies Improves, but Gaps Remain, Study in JNCCN Findson July 7, 2020 at 1:17 pm
JNCCN is the official journal of NCCN, a group of cancer center that develops treatment guidelines that are considered the “gold standard” for payers.
- JNCCN study explores if insurance is keeping pace with trends in targeted cancer therapyon July 7, 2020 at 1:06 pm
New research from the University of California, San Francisco (USCF) and City of Hope in the July 2020 issue of JNCCN--Journal of the National Comprehensive Cancer Network examines coverage trends for ...
- Early oncological control following partial gland cryo-ablation: a prospective experience specifying reflex MRI guided biopsy of the ablation zoneon July 7, 2020 at 10:37 am
Several consensus statements recommend serial serum prostate-specific antigen (PSA), multi parametric magnetic resonance imaging (mpMRI), and prostate biopsy following partial gland ablation. We ...
via Bing News